Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3406483 | 0.83 | TAAR1 (0.39) | PTGDR2SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL29781225 | 0.83 | TAAR1 (0.39) | PTGDR2SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL2807248 | 0.82 | PYCR1 (0.36) | PTGDR2SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL30831861 | 0.82 | PYCR1 (0.36) | PTGDR2SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL30352488 | 0.82 | PYCR1 (0.47) | PTGDR2SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL6673 | 0.82 | PYCR1 (0.47) | PTGDR2SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL8365116 | 0.79 | SMN1; SMN2 (0.41) | ALDH1A1LMNAMAPTPYCR1HPGD | |
| SCHEMBL2867783 | 0.79 | CA1 (0.38) | ALDH1A1LMNAMAPTPYCR1FFAR4 | |
| SCHEMBL795719 | 0.78 | PTGDR2 (0.48) | PTGDR2SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL29417721 | 0.78 | PTGDR2 (0.48) | PTGDR2SLC6A2SLC6A4ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559504-B2 | Benzotriazole derivative | UBE CORPORATION (JP) | 2026-02-24 | — | — | US | disclosed |
| US-12552757-B2 | NRF2-activating compound | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2026-02-17 | — | — | US | disclosed |
| US-20260028330-A1 | HETEROARYL CARBOXAMIDE AND RELATED GPR84 ANTAGONISTS AND USES THEREOF | LIMINAL BIOSCIENCES LTD (GB) | 2026-01-29 | — | — | US | disclosed |
| EP-3978073-B1 | 1H-BENZO[D][1,2,3]TRIAZOLE DERIVATIVES AS KEAP1 INHIBITORS FOR THE TREATMENT OF RENAL DISEASES | UBE CORP (JP) | 2025-10-15 | — | — | EP | disclosed |
| US-20250313573-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-10-09 | — | — | US | disclosed |
| US-12378200-B2 | Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors | ORSOBIO, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4565568-A1 | HETEROARYL CARBOXAMIDE AND RELATED GPR84 ANTAGONISTS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2025-06-11 | — | — | EP | disclosed |
| CN-120019047-A | Heteroaryl carboxamides and related GPR84 antagonists and uses thereof | 里米诺生物科学有限公司 | 2025-05-16 | — | — | CN | disclosed |
| WO-2025096654-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096662-A1 | COMPOSITIONS AND INHIBITORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2004000315-A1 | PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-31 | — | — | WO | disclosed |
| US-20030119670-A1 | Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-06-26 | — | — | US | disclosed |
| US-6489487-B1 | AGRICULTURAL OR HORTICULTURAL FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-03 | — | — | US | disclosed |
| EP-1238975-A1 | DIFLUOROMETHYLTRIAZOLONE COMPOUNDS, USE OF THE SAME AND INTERMEDIATES FOR THE PRODUCTION THEREOF | Sumitomo Chemical Company, Limited (JP) | 2002-09-11 | — | — | EP | disclosed |
| WO-1999063992-A9 | NOVEL CALCIUM CHANNEL DRUGS AND USES | ADVANCED MEDICINE INC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-1999064045-A9 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE INC (US) | 2001-07-05 | — | — | WO | disclosed |
| EP-1103548-A1 | TRIAZOLONE DERIVATIVES, USE THEREOF, AND INTERMEDIATE THEREFOR | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2001-05-30 | — | — | EP | disclosed |
| EP-1085863-A1 | CROSS-REFERENCE TO RELATED APPLICATIONS | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-1085863-A4 | CROSS-REFERENCE TO RELATED APPLICATIONS | ADVANCED MEDICINE INC (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999063992-A1 | NOVEL CALCIUM CHANNEL DRUGS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559504-B2 | Benzotriazole derivative | KEAP1, NFE2L2, NCOR1 | PTGDR2 2194/4885SLC6A2 874/4885SLC6A4 1175/4885 |
| US-12378200-B2 | Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (ACMSD) inhibitors | ALDH7A1, ACMSD, AMD1 | PTGDR2 1643/4885SLC6A2 2633/4885SLC6A4 2599/4885 |
| US-20260028330-A1 | HETEROARYL CARBOXAMIDE AND RELATED GPR84 ANTAGONISTS AND USES THEREOF | GPR84, GPR88, GPR68 | PTGDR2 180/4885SLC6A2 919/4885SLC6A4 981/4885 |
| US-12552757-B2 | NRF2-activating compound | NFE2L2, NFE2, KEAP1 | PTGDR2 1976/4885SLC6A2 2596/4885SLC6A4 2736/4885 |
| US-20250313573-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | KEAP1, NFE2L2, NQO1 | PTGDR2 103/4885SLC6A2 407/4885SLC6A4 346/4885 |
| US-20030119670-A1 | Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof | CYP51A1, DPM1, CYP1A1 | PTGDR2 4760/4885SLC6A2 4790/4885SLC6A4 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.